Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular ketamine versus haloperidol for control of aggressive emergency department patients
IRCT20180129038549N5Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine and haloperidol in agitation and intermittent explosive disorder (IED) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Patient aggression. Started Nov 2016; status: completed.
02
Drugs
ketaminehaloperidol
03
Conditions
agitationintermittent explosive disorder (IED)
Beyond the preview
Go deeper on IRCT20180129038549N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180129038549N5.